EPS for Cellect Biotechnology Ltd. (APOP) Expected At $-0.31

March 1, 2018 - By Vivian Currie

 EPS for Cellect Biotechnology Ltd. (APOP) Expected At $ 0.31

Analysts expect Cellect Biotechnology Ltd. (NASDAQ:APOP) to report $-0.31 EPS on March, 22.They anticipate $0.30 EPS change or 3,000.00 % from last quarter’s $-0.01 EPS. After having $-0.39 EPS previously, Cellect Biotechnology Ltd.’s analysts see -20.51 % EPS growth. The stock decreased 1.81% or $0.13 during the last trading session, reaching $7.08. About 12,251 shares traded. Cellect Biotechnology Ltd. (NASDAQ:APOP) has 0.00% since March 1, 2017 and is . It has underperformed by 16.70% the S&P500.

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. The company has market cap of $46.07 million. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. It currently has negative earnings.

More news for Cellect Biotechnology Ltd. (NASDAQ:APOP) were recently published by: Prnewswire.com, which released: “Cellect Biotechnology Announces $4 Million Registered Direct Offering” on January 29, 2018. Prnewswire.com‘s article titled: “Frost & Sullivan Publishes an Update Report on Cellect Biotechnology Ltd …” and published on February 01, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: